Evaluating the Compatibility of New Recombinant Protein Antigens (Trivalent NRRV) with a Mock Pentavalent Combination Vaccine Containing Whole-Cell Pertussis: Analytical and Formulation Challenges.

Haemophilus influenzae aluminum-salt adjuvant compatibility diphtheria formulation hepatitis B non-replicating rotavirus vaccine pediatric combination vaccine preservatives stability tetanus whole-cell pertussis

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
03 Jun 2024
Historique:
received: 08 04 2024
revised: 21 05 2024
accepted: 30 05 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: epublish

Résumé

Introducing new recombinant protein antigens to existing pediatric combination vaccines is important in improving coverage and affordability, especially in low- and middle-income countries (LMICs). This case-study highlights the analytical and formulation challenges encountered with three recombinant non-replicating rotavirus vaccine (NRRV) antigens (t-NRRV formulated with Alhydrogel

Identifiants

pubmed: 38932338
pii: vaccines12060609
doi: 10.3390/vaccines12060609
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Bill & Melinda Gates Foundation
ID : OPP1212920
Pays : United States

Auteurs

Prashant Kumar (P)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.

David A Holland (DA)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.

Kathryn Secrist (K)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.

Poorva Taskar (P)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.

Brandy Dotson (B)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.

Soraia Saleh-Birdjandi (S)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.

Yetunde Adewunmi (Y)

New York State Department of Health, Division of Infectious Diseases, Wadsworth Center, Albany, NY 12208, USA.

Jennifer Doering (J)

New York State Department of Health, Division of Infectious Diseases, Wadsworth Center, Albany, NY 12208, USA.

Nicholas J Mantis (NJ)

New York State Department of Health, Division of Infectious Diseases, Wadsworth Center, Albany, NY 12208, USA.

David B Volkin (DB)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.

Sangeeta B Joshi (SB)

Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.

Classifications MeSH